Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure

References

• Lalwani AK, Goldstein JA, Kelley MJ, Luxford W, Castelein CM, Mhatre AN. Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9. Am J Hum Genet. 2000;67(5):1121–1128. doi:10.1016/S0002-9297(07)62942-5.
   PubMed Web of Science ®Google Scholar
• Kunishima S, Kojima T, Matsushita T, Tanaka T, Tsurusawa M, Furukawa Y, Nakamura Y, Okamura T, Amemiya N, Nakayama T, et al. Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May–Hegglin anomaly/Sebastian syndrome). Blood. 2001;97(4):1147–1149. doi:10.1182/blood.V97.4.1147.
   PubMed Web of Science ®Google Scholar
• Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo Nigro C, Ghiggeri GM, Ravazzolo R, Savino M, Del Vecchio M, et al. Mutations in MYH9 result in the May–Hegglin anomaly, and Fechtner and Sebastian syndromes. The may-hegglin/Fechtner syndrome consortium. Nat Genet. 2000;26(1):103–105. doi:10.1038/79063.
   PubMed Web of Science ®Google Scholar
• Global Variome shared LOVD. The MYH9 Gene Homepage. [accessed 2022 Feb 13]. https://databases.lovd.nl/shared/genes/MYH9.
   Google Scholar
• Junt T, Schulze H, Chen Z, Massberg S, Goerge T, Krueger A, Wagner DD, Graf T, Italiano JE Jr, Shivdasani RA, et al. Dynamic visualization of thrombopoiesis within bone marrow. Science. 2007;317(5845):1767–1770. doi:10.1126/science.1146304.
   PubMed Web of Science ®Google Scholar
• Pecci A, Biino G, Fierro T, Bozzi V, Mezzasoma A, Noris P, Ramenghi U, Loffredo G, Fabris F, Momi S, et al. Alteration of liver enzymes is a feature of the Myh9-related disease syndrome. PLOS ONE. 2012;7(4):e35986. doi:10.1371/journal.pone.0035986.
   PubMed Web of Science ®Google Scholar
• Pecci A, Ma X, Savoia A, Adelstein RS. MYH9: structure, functions and role of non-muscle myosin IIA in human disease. Gene. 2018;664:152–167. doi:10.1016/j.gene.2018.04.048.
   PubMed Web of Science ®Google Scholar
• Bastida JM, Gonzalez-Porras JR, Rivera J, Lozano ML. Role of thrombopoietin receptor agonists in inherited thrombocytopenia. Int J Mol Sci. 2021;22(9):4330. doi:10.3390/ijms22094330.
   PubMed Web of Science ®Google Scholar
• Shirley M. Avatrombopag: first global approval. Drugs. 2018;78(11):1163–1168. doi:10.1007/s40265-018-0949-8.
   PubMed Web of Science ®Google Scholar
• Markham A. Avatrombopag: a review in thrombocytopenia. Drugs. 2021;81(16):1905–1913. doi:10.1007/s40265-021-01613-y.
   PubMed Web of Science ®Google Scholar
• Savoia A, De Rocco D, Panza E, Bozzi V, Scandellari R, Loffredo G, Mumford A, Heller PG, Noris P, De Groot MR, et al. Heavy chain myosin 9-related disease (MYH9-RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thromb Haemost. 2010;103(4):826–832. doi:10.1160/TH09-08-0593.
   PubMed Web of Science ®Google Scholar
• MutationTaster. [accessed 2022 Feb 13]. https://www.mutationtaster.org.
   Google Scholar
• Pecci A, Klersy C, Gresele P, Lee KJ, De Rocco D, Bozzi V, Russo G, Heller PG, Loffredo G, Ballmaier M, et al. MYH9 -related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations. Hum Mutat. 2014;35(2):236–247. doi:10.1002/humu.22476.
   PubMed Web of Science ®Google Scholar
• Saposnik B, Binard S, Fenneteau O, Nurden A, Nurden P, Hurtaud-Roux MF, Schlegel N. Mutation spectrum and genotype-phenotype correlations in a large French cohort of MYH9-related disorders. Mol Genet Genomic Med. 2014;2(4):297–312. doi:10.1002/mgg3.68.
   PubMedGoogle Scholar
• Seri M, Pecci A, Di Bari F, Cusano R, Savino M, Panza E, Nigro A, Noris P, Gangarossa S, Rocca B, et al. MYH9-related disease: may-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine. 2003;82(3):203–215. doi:10.1097/01.md.0000076006.64510.5c.
   PubMed Web of Science ®Google Scholar
• Pecci A, Gresele P, Klersy C, Savoia A, Noris P, Fierro T, Bozzi V, Mezzasoma AM, Melazzini F, Balduini CL. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood. 2010;116(26):5832–5837. doi:10.1182/blood-2010-08-304725.
   PubMed Web of Science ®Google Scholar
• Zaninetti C, Barozzi S, Bozzi V, Gresele P, Balduini CL, Pecci A. Eltrombopag in preparation for surgery in patients with severe MYH9-related thrombocytopenia. Am J Hematol. 2019;94(8):E199–E201. doi:10.1002/ajh.25500.
   PubMed Web of Science ®Google Scholar
• Deng J, Hu H, Huang F, Huang C, Huang Q, Wang L, Wu A, Yang J, Qin D, Zou W, et al. Comparative efficacy and safety of thrombopoietin receptor agonists in adults with thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trial. Front Pharmacol. 2021;12:704093. doi:10.3389/fphar.2021.704093.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, Vredenburg M, Cuker A. Switching from eltrombopag or romiplostim to avatrombopag in immune thrombocytopenia: a multicenter study of U.S. ITP Referral Centers [abstract]. Res Pract Thromb Haemost. 2021;5(Suppl 2). doi:10.1002/rth2.12591.
   PubMedGoogle Scholar
• Lee EJ, Seshadri M, Bussel JB. Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists. Am J Hematol. 2021;96(10):E373–E376. doi:10.1002/ajh.26277.
   PubMed Web of Science ®Google Scholar
• Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, Luengo JI, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009;27(2):424–430. doi:10.1634/stemcells.2008-0366.
   PubMed Web of Science ®Google Scholar
• Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2004;25(2):52–60. doi:10.1016/j.cyto.2003.05.001.
   PubMed Web of Science ®Google Scholar
• Gilreath J, Lo M, Bubalo J. Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs. 2021;81(11):1285–1305. doi:10.1007/s40265-021-01553-7.
   PubMed Web of Science ®Google Scholar
• Fukushima-Shintani M, Suzuki K, Iwatsuki Y, Abe M, Sugasawa K, Hirayama F, Kawasaki T, Nakahata T. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009;82(4):247–254. doi:10.1111/j.1600-0609.2008.01198.x.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Rev. 2022;53:100909. doi:10.1016/j.blre.2021.100909.
   PubMed Web of Science ®Google Scholar